Leukemia is a heterogeneous disease characterized by specific genetic alterations and related multiple epigenetic changes.[5] DNA methyltransferase 3A (DNMT3A) mutations have been found in approximately 20% to 25% of adult AML patients and only 0% to 1.4% of childhood AML.[5–20] The hotspots of mutations are mainly located in the catalytic methyltransferase domain, hereinto, mutation R882 accounts for 60%, which conferred significant adverse prognostic impact.[5–19,21] However, the prognostic significance of other DNMT3A mutations in AML is to be determined. The gene discussed is DNMT3A; the disease is leukemia.